Skip Navigation

Japanese Journal of Clinical Oncology 2008 38(10):715-718; doi:10.1093/jjco/hyn095
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wakabayashi, T.
Right arrow Articles by Yoshida, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wakabayashi, T.
Right arrow Articles by Yoshida, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2008). Published by Oxford University Press. All rights reserved

A Multicenter Phase I Trial of Interferon-β and Temozolomide Combination Therapy for High-grade Gliomas (INTEGRA Study)

Toshihiko Wakabayashi1, Takamasa Kayama2, Ryo Nishikawa3, Hiroshi Takahashi4, Toshiki Yoshimine5, Nobuo Hashimoto6, Tomokazu Aoki7, Kaoru Kurisu8, Atsushi Natsume1, Masatoshi Ogura1 and Jun Yoshida1

1 Department of Neurosurgery, Nagoya University School of Medicine, Nagoya
2 Department of Neurosurgery, Yamagata University School of Medicine, Yamagata
3 Department of Neurosurgery, Saitama Medical University, Saitama
4 Department of Neurosurgery, Nippon Medical School, Tokyo
5 Department of Neurosurgery, Osaka University School of Medicine, Osaka
6 Department of Neurosurgery, Kyoto University School of Medicine, Kyoto
7 Department of Neurosurgery, Kitano Hospital, Osaka
8 Department of Neurosurgery, Hiroshima University School of Medicine, Hiroshima, Japan

For reprints and all correspondence: Toshihiko Wakabayashi, Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan. E-mail: wakabat{at}med.nagoya-u.ac.jp

Received June 24, 2008; accepted August 14, 2008

A multicenter phase I clinical trial, namely, Integrated Japanese Multicenter Clinical Trial: A Phase I Study of Interferon-β and Temozolomide for Glioma in Combination with Radiotherapy (INTEGRA Study), is being conducted for patients with high-grade glioma in order to evaluate the safety, feasibility and preliminary clinical effectiveness of the combination of interferon-β and temozolomide. The primary endpoint is incidence of adverse events. The secondary endpoints are progression-free survival time and overall survival time. In addition, objective tumor response will be evaluated in a subpopulation of patients with the measurable disease. The reduction rate of tumor will be calculated according to Response Evaluation Criteria In Solid Tumors for measurable tumors as determined by magnetic resonance imaging. Subsequently, the overall response will be evaluated based on the results of measurable and non-measurable tumors. Ten newly diagnosed and 10 recurrent patients will be enrolled in this study.

Key Words: chemo-phase I-II-III • clinical trials • CNS


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.